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Abstract
We report a patient who developed drug-eluting stent (DES) thrombosis induced by discontinuation of dual
antiplatelet therapy (DAPT) and subsequently had a massive surgical site bleed caused by restarting heparin and
DAPT during the perioperative period.
An 85-year-old man visited a local hospital owing to complaints dyspnea. He was diagnosed with laryngeal cancer
and was scheduled for a total laryngectomy. Preoperative examinations showed an anteroseptal myocardial
infarction. A DES was placed at segment 6 of the coronary artery and DAPT was initiated 27 days before surgery.
After admission to our hospital, DAPT was replaced with unfractionated heparin. On the operation day, heparin was
discontinued, and a tracheotomy, total laryngectomy and right hemi-thyroidectomy were performed. While
recovering from anesthesia, ischemic ST elevation appeared. Cardiac catheterization revealed complete obstruction
of the DES by a white thrombus. After recanalization, heparin and DAPT were restarted, and bleeding occurred.
The next day, total blood loss was 2755 mL and surgical hemostasis was performed.
Because his serum creatine kinase value was elevated at the cessation of heparin, anticoagulation by unfractionated
heparin could not have prevented platelet thrombosis. Therefore, we should performed the tracheostomy to secure
the patient’s airway under DAPT or only aspirin therapy a month after the DES implantation, and performed the
laryngectomy and right hemi-thyroidectomy five months after the first surgery. This case is serious warnings of
perioperative major adverse cardiac events induced by discontinuation of DAPT; unfractionated heparin was an
insufficient safeguard against platelet thrombosis, and perioperative massive bleeding induced by restarting
antiplatelet and anticoagulation therapy. In addition, a series of human errors, which the cardiologist chosen DES
regardless of scheduled total larygectomy, the discontinuation of antiplatelet therapy shortly after a DES placement,
and the surgical staffs failed to share the elevated serum CK and CK-MB values, caused life-threatening complications.
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Background
Obstruction of a drug eluting stent (DES) during the
perioperative period is a possible and potentially lethal
complication of the procedure. To prevent the obstruc-
tion of a DES, dual antiplatelet therapy (DAPT), consist-
ing of aspirin and a P2Y12 receptor inhibitor, should be
continued for at least a year after DES placement [1].
Therefore, treatment with a bare-metal stent (BMS),
which needs DAPT for at least a month [1], and/or plain
old balloon angioplasty (POBA) are recommended for
patients who have ischemic heart disease and are antici-
pating non-cardiac surgery [1]. In patients undergoing
emergency surgery within a month of DES placement,
assessing the risk of bleeding or DES obstruction is diffi-
cult. Herein, we report a patient who developed both
DES thrombosis and a massive surgical site bleed during
the perioperative period.
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Case presentation
An 85-year-old man, preserving normal cognitive function,
complained of progressive dyspnea and visited a local hos-
pital, where he was diagnosed with laryngeal cancer and
scheduled for a total laryngectomy. A preoperative electro-
cardiogram and echocardiography showed anteroseptal
myocardial infarction without symptoms. On 27 days be-
fore the laryngectomy, the cardiologist at the local hospital
placed a DES at segment 6 (#6) of the anterior descending
coronary artery and initiated DAPT, including 100 mg of
aspirin and 75 mg of clopidogrel, despite the cardiologist
recognized the patient was scheduled laryngectomy. Then,
he was admitted to our hospital 10 days before the laryn-
gectomy. Preoperative echocardiography showed antero-
septal hypokinesis and a left ventricular ejection fraction of
36 %. A 12-lead electrocardiogram showed a slight ische-
mic ST elevation in leads V1-3 and an abnormal ST-T in
leads aVL and V2-6 (Fig. 1). Cardiologists at our hospital
assessed that the patient’s myocardium perfused by #6 had
no function, and obstruction of the DES would have little
effect on cardiac function from the echocardiographic
finding. The cardiologists started 400 U/h of unfractio-
nated heparin as a substitute for DAPT 6 days before the
laryngectomy. Five days before the laryngectomy, we were
consulted about the patient and warned the surgeons
about the risks associated with discontinuation of DAPT.
Six hours before the laryngectomy, heparin was discontin-
ued. The surgeons checked the serum creatine kinase
(CK), CK-MB and activated partial thromboplastin time
(aPTT) values at the cardiologist’s direction, three hours
before the laryngectomy. An hour before the laryngec-
tomy, a central clinical laboratory staff noticed the abnor-
mal values of the CK and CK-MB (Table 1), which were
reported to one of the surgeons by phone. The reported
surgeon failed to inform us about the abnormal values.
The patient entered the operating room in a wheelchair.
He showed no significant changes in 3-lead electrocardio-
gram and did not complain of a chest pain. Oxygenation
and 3 mg/h of nicorandil were started, and an arterial line
was placed. Then, tracheotomy was performed under
regional anesthesia with supplementation of fentanyl.
After the tracheal intubation via tracheostomy, general
anesthesia was induced and maintained with propofol
(2.5–1.3 μg/mL), remifentanil (0.33–0.13 μg/kg/min), fen-
tanyl (total: 0.3 mg) and rocuronium. Circulation was sup-
ported by continuous nicorandil and phenylephrine, and
bolus ephedrine. A total laryngectomy and right hemi-
thyroidectomy were performed. Duration of the surgery
was 211 min, and blood loss during surgery was 7 mL.
Little change was observed in his 3-lead electrocardiogram
during surgery. After the completion of surgery, anesthetic
agents were discontinued. During recovery from anesthesia,
the patient’s heart rate and arterial pressure elevated to
100/min and 190/80 mmHg, respectively, and 0.5 mV of
ischemic ST elevation was confirmed in lead II of the elec-
trocardiogram. Therefore, the intravenous nicorandil was
Fig. 1 Preoperative 12-lead electrocardiography of the patient, showing slight ischemic ST elevation in leads V1-3 and abnormal ST-T in
leads aVL and V2-6
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increased to 6 mg/h and bolus nicardipine (0.4 mg) and
landiolol (10 mg) were administered for reduction of blood
pressure and heart rate. The 12-lead electrocardiogram
showed an ischemic ST elevation in leads V1-5 (Fig. 2), and
the patient complained of chest pain with gestures after
recovery. A bolus of 10 mg of morphine and continuous
1 μg/kg/min of isosorbide dinitrate were administered and
we quickly called the cardiologist, who immediately decided
to perform percutaneous coronary intervention. The pa-
tient was transferred to the cardiac catheterization labora-
tory under sedation by dexmedetomidine (0.4 μg/kg/h).
We regretted to find the elevated CK and CK-MB values at
the time. At the laboratory, complete obstruction of the
DES was observed (Fig. 3), and aspiration of the white
thrombus, caused by a subacute thrombosis (SAT), was
performed. After recanalization of the DES (Fig. 4), the pa-
tient’s chest pain and the ST elevation in the electrocardio-
gram disappeared, and 400 U/h of unfractionated heparin
was restarted. After that, the patient was transferred to the
intensive care unit (ICU), where 100 mg of aspirin and
3.75 mg of prasugrel were administered through a feeding
tube. Then, bleeding from the surgical site began and
the patient’s hemodynamic status gradually deteriorated.
Therefore, heparin, aspirin and prasugrel were stopped.
On the morning of the 1st postoperative day (POD), the
patient’s aPTT was still markedly prolonged (Table 1), and
the total blood loss reached 2755 mL. In addition,
1120 mL of red blood cells (RBCs) and 480 mL of fresh
frozen plasma (FFP) were transfused. Thereby, surgical
hemostasis and transfusion of RBCs (920 mL) and FFP
(480 mL) were performed. Aspirin and prasugrel were
restarted on the 3rd POD. Hemorrhage and re-occlusion
of DES did not reoccur, and the patient was discharged on
foot on the 34th POD.
Discussion
2014 ACC/AHA guideline recommend that, for patients
who require PCI but are scheduled for elective non-
cardiac surgery in the subsequent 12 months, balloon
angioplasty or BMS implantation followed by 4 to
6 weeks of DAPT are reasonable strategies [1]. For pa-
tients with DES who must undergo urgent surgical pro-
cedures that mandate the discontinuation of DAPT,
however, it is reasonable to continue aspirin if possible
and restart the P2Y12 inhibitor as soon as possible in
the immediate postoperative period [1, 2]. And the study
showed that incidence of major adverse cardiac event
Table 1 Serum creatine kinase, creatine kinase MB, and






1 POD 2 POD 5 POD 6 POD
Morning Evening
CK (U/L) 84 1345 2485 1690 980 212 164
CK-MB (U/L) 8 175 364 247 59 11 10
aPTT (s) 32.8 44.8 - 94.2 44.6 - -
POD postoperative day, CK creatine kinase, CK-MB creatine kinase MB,
aPTT activated partial thromboplastin time
Fig. 2 Postoperative 12-lead electrocardiography of the patient, showing ischemic ST elevation in leads V1-5
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(MACE) was significantly higher (10–15 %) during the
first 30 days after the stent implantation [3]. In our case,
placement of a DES was the primary issue for the patient,
who urgently required tracheostomy because of airway
narrowing. The discontinuation of antiplatelet therapy
shortly after the myocardial infarction and DES placement
induced the SAT, which was the secondary issue.
Bridging with anticoagulants, such as low-molecular-
weight heparin, after interruption of DAPT during the
perioperative period is advised [2]. In Japan, unfractio-
nated heparin, having no evidence and used empirically,
is also advised [4]. But the newer perioperative guideline
recommend continue DAPT in patients undergoing ur-
gent noncardiac surgery during the first 4 to 6 weeks
after BMS or DES implantation unless the risk of bleeding
outweights the benefit of stent thrombosis prevention [1].
In addition, there has not been any evidence demonstrat-
ing the efficacy of bridging with anticoagulants using hep-
arin. In this case, we performed anticoagulation therapy
using unfractionated heparin. Nevertheless, the serum
CK-MB value of the patient was elevated at the time of
cessation of heparin despite a slightly prolonged aPTT
(Table 1). The all surgical staffs failed to share the elevated
serum CK and CK-MB values at that point and failed to
cancel the surgery, which were the third issue. And a
white thrombus in the DES was confirmed at the time of
recanalization. Although his preoperative aPTT was not
markedly prolonged, anticoagulant therapy of 400 U/h of
unfractionated heparin could not have prevented platelet
thrombosis in this case.
It has been reported that the cumulative incidences of
bleeding 30 days after surgical procedures were signifi-
cantly higher in patients with DAPT than in patients
with single or no antiplatelet therapy [5]. In this case,
the first surgery was performed after discontinuation of
both antiplatelet and anticoagulation therapy. Therefore,
surgical hemostasis was easily obtained and not strictly
performed, and bleeding only became obvious after
restarting heparin and DAPT. If the surgery was per-
formed under continuous DAPT, however, similar or
massive bleeding might have occurred in the periopera-
tive period. Because the patient had been placed a DES,
we should have first performed the tracheostomy on the
patient with strict hemostasis to secure the airway under
continuation of DAPT or only aspirin a month after the
DES implantation. Then, six months after the DES im-
plantation, we should have performed the laryngectomy
and right hemi-thyroidectomy [1].
Because the patient might have mild impairment in
expression of chest pain due to progressive laryngeal
cancer and/or feel little pain due to nerve damage by old
myocardial infarction, the patient could complained less
chest pain at the time of visiting to local hospital and
entering the operation room, which could induced mis-
judgment. And a series of human errors occurred and
caused life-threatening complications. Human errors
were as follows: the cardiologist at the local hospital
chosen DES instead of BMS or POBA regardless of
scheduled total larygectomy; the root cause of this inci-
dent, the discontinuation of antiplatelet therapy shortly
after the myocardial infarction and DES placement, and
Fig. 3 Coronary angiography in the right anterior oblique position
after the surgery, showing the left coronary artery and obstruction of
segment 6
Fig. 4 Coronary angiography in the right anterior oblique position
during recanalization, showing the obstructed region in the placed
drug eluting stent
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the all surgical staffs failed to share the elevated serum
CK and CK-MB values and failed to cancel the surgery.
After this case, we proposed to create the hospital task
force for updating and promoting the perioperative PCI,
antiplatelet and anticoagulation procedures. This task
force consisted of the representatives from departments
of all surgery, anesthesiology, cardiology, gastroenterology,
pharmacy and hospital medical safety management office.
Then, this task force announced the updated those proce-
dures in our hospital. And now we are exploring a method
of enhancing the detection of laboratory test abnormality
shortly before the surgery.
Conclusion
Because the patient had airway stenosis with a recent place-
ment of DES, we should have first performed the tracheos-
tomy on the patient with strict hemostasis to secure the
airway under continuation of DAPT or only aspirin a
month after the DES implantation. Then, six months after
the DES implantation, we should have performed the laryn-
gectomy and right hemi-thyroidectomy. This case is serious
warnings of perioperative MACE induced by discontinu-
ation of DAPT; 400 U/h of unfractionated heparin was an
insufficient safeguard against platelet thrombosis, and peri-
operative massive bleeding then induced by restarting anti-
platelet and anticoagulation therapy. In addition, a series of
human errors, which the cardiologist at local hospital
chosen DES regardless of scheduled total larygectomy, the
discontinuation of antiplatelet therapy, and the surgical
staffs failed to share the elevated serum CK and CK-MB
values, caused life-threatening complications. Anesthesiolo-
gists should promote the information about the periopera-
tive risks and managements of PCI and DAPT to surgeons
and cardiologists further widely.
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